SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a confluence of negative sentiment, including a federal jury finding that Elon Musk defrauded Twitter shareholders and concerns regarding broader macroeconomic instability. The community is deeply divided, with bears pointing to falling delivery numbers and operational scrutiny as evidence of a structural decline, while loyal bulls continue to highlight upcoming projects like TeraFab and the potential for a rebound as reasons to maintain their positions.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and downward pressure as investors weigh recent acquisition activity against broader macroeconomic headwinds, including geopolitical tensions and fluctuating construction market sentiment. Despite the bearish pressure, the community remains actively divided, with many long-term shareholders continuing to express confidence in CEO Brad Jacobs' consolidation strategy while others closely monitor for the next M&A catalyst or integration updates.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors capitalize on its recent NYSE listing, which provides rare public market access to high-profile private AI and tech companies like Anthropic, OpenAI, and SpaceX. While the community is actively debating the significant premium over the fund's net asset value and the impact of a six-month lockup on available float, many are focused on the stock's high volatility and potential for momentum-driven price swings.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is currently trending due to a major data breach involving approximately 33 million accounts, sparking intense regulatory scrutiny, a nationwide boycott in South Korea, and a significant leadership shake-up. Investors are actively debating the potential for long-term recovery against the backdrop of mounting legal liabilities, government investigations, and consumer backlash that threatens to disrupt the company's core market.

Select Sector SPDR Trust (The) - State Street Consumer Discretionary Select Sector SPDR ETF

Consumer Discretionary Select Sector SPDR Fund

Consumer Discretionary is facing significant downward pressure as market participants weigh the potential impact of ongoing tariff negotiations on household spending and corporate margins. Community discussions highlight a persistent rotation into defensive sectors, with sentiment cautious as investors closely monitor key weightings like Amazon and Tesla for signs of a technical floor.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is currently capturing significant market interest as it benefits from surging demand for AI-driven chip fabrication equipment, with community members actively monitoring its strong relative strength against industry peers. Investors are closely tracking upcoming earnings while debating the stock's valuation and potential upside against the backdrop of broader semiconductor sector consolidation.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone shares are under pressure as investors react to mixed signals regarding private credit exposure and shifting regulatory landscapes, despite the firm reporting a significant earnings beat and record assets under management. Market participants are actively debating whether the recent dip represents a buying opportunity in a high-growth financial leader or a warning sign of broader systemic risks within the alternative asset sector.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors focus on its integration into the AI-native economy, with community discussion highlighting its role in chain abstraction, privacy-focused protocols, and recent infrastructure developments. Many are closely watching the balance between retail accumulation and institutional activity while expressing optimism about its long-term utility in the decentralized AI landscape.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is actively being discussed as a major player in the private credit and infrastructure space, with investors noting a positive trend following record fee-related earnings and significant capital raising milestones. The community remains focused on KKR's ongoing pivot toward permanent capital and wealth management, viewing the stock as a compelling long-term play despite broader market volatility and questions surrounding the liquidity of private markets.

Select Sector SPDR Trust (The) - State Street Industrial Select Sector SPDR ETF

Industrial Select Sector SPDR Fund

The Industrial Select Sector SPDR Fund (XLI) is trending as investors rotate toward cyclical sectors like industrials and financials, with market participants closely monitoring industrial production data, USTR investigations into trade practices, and the impact of geopolitical volatility on supply chains. The community is actively discussing the fund's technical support levels and the potential for a manufacturing-led rotation as earnings reports across infrastructure, housing, and industrial services provide critical insights into margin resilience.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Humacyte (HUMA) Projected to Post Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...

<ul class="summary-bullets"><li>Humacyte is looking to sell 25 million shares in order to raise $20 million.</li><li>The company said it plans to use the proceeds to support the commercialization of Symvess for vascular trauma.</li><li>Humacyte also agreed not to pursue other commercialization negotiations in Saudi Arabia until July 2026.</li></ul>Shares of Humacyte, Inc. (HUMA) tanked more than 20% to an all-time low on Thursday, after the company announced a $20 million fundraising at a significant discount to the stock’s closing price a day earlier.Simultaneously, the company also announced a $1.5 million minimum purchase commitment from Saudi Arabia for its&nbsp;Symvess, a bioengineered, off-the-shelf human blood vessel.Humacyte signed a new securities purchase agreement with several new institutional investors to sell 25 million shares of common stock in a registered direct offering. The deal is expected to generate gross proceeds of about $20 million and is slated to close around March 20, 2026. This translates to $0.80 per share, a 25% discount to the stock’s Wednesday closing price of $1.06.The company added that it plans to use the proceeds to support the commercialization of Symvess for vascular trauma, advance a Biologics License Application (BLA) supplement for hemodialysis use, and fund ongoing clinical and pipeline development programs.<h2 class="st-heading-2">Humacyte Is In Talks To Form JV In Saudi Arabia</h2>Humacyte said the order will support a clinical evaluation and outreach program in hospitals across Saudi Arabia. The company is also in talks to form a joint venture and secure commercialization rights for Symvess in the country.Humacyte will train local medical professionals to use the product and has agreed not to pursue any other commercialization negotiations in Saudi Arabia until July 2026. While Symvess is FDA-approved for the treatment of extremity vascular trauma, other uses remain investigational.“The clinical evaluation and outreach program is designed to build awareness and understanding of the Symvess technology among healthcare providers as we pursue regulatory approval and prepare for potential commercial launch in the KSA,” said Laura Niklason, Founder and CEO of Humacyte.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.One user believes <a href="https://stocktwits.com/symbol/HUMA">HUMA</a> is a “great candidate” for a reverse stock split.<stembedurl>https://stocktwits.com/Morslan/message/647964164</stembedurl>Another user expects the stock to fall to $0.3. It is currently trading around $0.8.<stembedurl>https://stocktwits.com/paulN98/message/647972889</stembedurl>Year-to-date, the stock has declined around 10%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rivn-stock-jump-in-pre-market-today/cZ3aSSTRIhb">Uber Expands Autonomous Vehicle Push - Here’s Everything To Know About Its Partnership With Rivian</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stocks chart. (Image Courtesy: Getty Images)

Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?

The company said it is in talks to form a joint venture and secure commercialization rights for Symvess, a bioengineered blood vessel, in Saudi Arabia.

Equity

Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday...

Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional...

D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Thursday...

Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One...

Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.

Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Monday...

<ul class="summary-bullets"><li>The National Defense Authorization Act for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies to fix severe artery injuries in arms and legs.</li><li>This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.</li><li>Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.</li></ul>Humacyte Inc. (HUMA) on Monday announced that the recently adopted FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels.The company stated that the DOD funding is intended to support the evaluation and incorporation of biologic vascular repair technologies for warfighters with traumatic vascular injuries.Humacyte stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).<a href="https://stocktwits.com/symbol/HUMA">Humacyte shares</a> were up more than 30% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Does The NDAA Say?</h2>The National Defense Authorization Act (NDAA) for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies&nbsp;to fix severe artery injuries in arms and legs.This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.Autologous vein harvesting refers to the surgical removal of the patient’s own healthy vein, which is usually the great saphenous vein (GSV) in the leg. This is used as a graft, typically in coronary artery bypass grafting (CABG) or peripheral vascular surgery.“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” said Humacyte founder and CEO, Laura Niklason.<h2 class="st-heading-2">What Is Humacyte’s Symvess?</h2>Symvess is a human-derived biologic vessel&nbsp;used when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible.The company says Symvess is off-the-shelf and ready to use, with no immune response observed to date. It also states that Symvess has low susceptibility to infection.Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> is up 26% year-to-date, but down 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

HUMA
Humacyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HUMA News

HUMAHumacyte Inc